German-Danish vaccine manufacturer Bavarian Nordic A/S received a new order valued at USD 120 million by the U.S. Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response at the U.S. Department of Health and Human Services, primarily covering the manufacturing of new bulk product for the Company’s smallpox/mpox vaccine.
The bulk product, representing USD 96 million of the contract value, will be manufactured and invoiced in 2023 and will only partly restore the inventory, which was used to manufacture vaccines in response to the mpox outbreak in 2022.
Nearly 5.5 million doses have been manufactured for the U.S. government over the course of 2022 and 2023, and replenishment of the bulk inventory is necessary to fulfil the Company’s long-term commitment to deliver a freeze-dried version of the vaccine for U.S. smallpox preparedness.
In addition, Bavarian Nordic will manufacture and supply additional liquid-frozen doses of the vaccine in 2023, valued at USD 3 million. The agreement includes additional services totalling USD 21 million, of which the majority will be received in 2024 and 2025.